口服托法替布对比地塞米松口服小脉冲治疗活动性非节段性白癜风的随机对照试验
这项前瞻性、随机、研究者盲法试验纳入60例18-60岁活动性非节段性白癜风患者,比较地塞米松2.5 mg每周两次(A组)与口服托法替布5 mg每日两次(B组)治疗24周后观察12周。结论认为托法替布优于口服小脉冲疗法。
要点
- 24周时两组≥50% VES改善比例无显著差异(16.7% vs 20.0%)。
- 36周时托法替布组VES下降幅度显著大于地塞米松组。
- 12周时地塞米松组治疗失败率更高(20% vs 3.3%)。
核心结论
- 托法替布在治疗活动性非节段性白癜风方面比口服小脉冲地塞米松更有效。
研究设计与样本
- 前瞻性、随机、研究者盲法试验,招募18-60岁活动性非节段性白癜风患者。
- 共60例患者随机分组(每组30例),49例完成36周。
- A组接受地塞米松2.5 mg每周两次,B组接受口服托法替布5 mg每日两次,治疗24周后观察12周。
临床怎么用
- 对于活动性非节段性白癜风,可考虑口服托法替布5 mg每日两次作为治疗选择。
局限性
- 样本量有限。
- 单中心设计。
- 缺乏双盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of literature on stabilizing and repigmenting potential of oral tofacitinib in active vitiligo. OBJECTIVE: To compare the efficacy of oral tofacitinib with oral mini-pulse therapy in active vitiligo. METHODS: This prospective, randomized, investigator-blinded trial recruited patients aged 18-60 with active nonsegmental vitiligo. Participants were randomized to receive dexamethasone 2.5 mg twice a week (group A) or oral tofacitinib 5 mg twice daily (group B) for 24 weeks, followed by 12 weeks of observation. The primary outcome was the proportion of patients showing ≥50% improvement in vitiligo extent score (VES) at 24 weeks. RESULTS: Sixty patients were recruited (30 per group), with 49 completing 36 weeks. At 24 weeks, the proportion achieving ≥50% VES improvement was similar (16.7% vs 20.0%, P = .833). By 36 weeks, group B had a significantly greater VES decrease (31.5 ± 24.9% vs 16.7 ± 34.8%, P = .031). Group A had higher treatment failure at 12 weeks (20% vs 3.3%, P = .049), but comparable stabilization rates at 24 weeks (63.3% vs 83.3%, P = .171). LIMITATIONS: Limited sample size, single-center design, and lack of double-blinding. CONCLUSION: Tofacitinib is more effective than oral mini-pulse (dexamethasone 2.5 mg twice a week) for treating active nonsegmental vitiligo.
引用
- Dev A, Vinay K, Bishnoi A, et al. Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial. J Am Acad Dermatol. 2025. PMID: 40637677. doi:10.1016/j.jaad.2025.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。